Don’t Reassign Lots Without a Verified and Traceable Audit Trail

Do Not Reassign Product Lots Without Maintaining a Verified Audit Trail

Remember: Never change or reassign lot numbers without a fully documented and traceable audit trail authorized by Quality Assurance.

Why This Matters in GMP

Lot numbers are unique identifiers that allow pharmaceutical companies to trace every step of a product’s lifecycle — from raw material procurement to final distribution. Reassigning lot numbers without appropriate documentation undermines traceability, opens the door to fraud or data tampering, and obscures root cause analysis during complaints or recalls. An audit trail ensures that any lot change is intentional, approved, and verifiable — thereby maintaining product and data integrity.

Also Read: The Role of GMP in the Design and Production of IMPs for Biopharmaceuticals

For example, if a warehouse staff member manually changes a lot number label without QA review or documented rationale, it becomes nearly impossible to trace the correct batch history in the event of a market complaint. Reassignment without records can also invalidate stability studies, misalign retention samples, and impact serialization compliance. Such actions are seen as data integrity breaches and are taken very seriously by regulators.

Regulatory and Compliance Implications

21 CFR Part 211.188 requires complete batch production records, including traceable lot numbers. EU GMP Chapter 4 mandates that all

changes must be recorded with justification, approval, and impact assessment. WHO GMP also emphasizes documentation accuracy and audit trail maintenance as part of data integrity controls.

Also Read: Never Blend Different Product Lots Without Prior QA Approval

During audits, inspectors review batch manufacturing records, label reconciliation logs, deviation reports, and audit trail data (especially in e-records). Unauthorized or poorly documented lot reassignments are considered critical violations that may result in product recalls, import bans, or enforcement actions. Traceability gaps suggest that the manufacturer cannot guarantee product quality or ensure patient safety.

Implementation Best Practices

Establish strict controls through SOPs that prohibit manual or unapproved lot changes. All reassignment requests should be initiated through deviation procedures, assessed for impact, and approved by QA. Maintain change control records that include the reason for reassignment, affected documents, system updates, and any required relabeling.

Also Read: Never Open Both Airlock Doors Simultaneously in GMP Cleanrooms

For electronic systems, enable full audit trail logging and restrict lot modification rights to QA administrators. For physical labels, implement tamper-evident seals and barcode scanning to detect inconsistencies. Train staff to escalate any lot-related errors rather than attempting informal corrections. Periodically audit lot assignment and tracking practices to ensure full alignment with GMP expectations.

Regulatory References

– 21 CFR Part 211.188 – Batch production and control records
– EU GMP Chapter 4 – Documentation
– WHO TRS 996, Annex 5 – Data integrity in GMP
– PIC/S PI 041 – Inspection of Data Integrity Systems